Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor "holiday" in solid organ transplant patients with acute renal dysfunction

被引:32
作者
Cantarovich, M
Metrakos, P
Giannetti, N
Cecere, R
Barkun, J
Tchervenkov, J
机构
[1] McGill Univ, Hlth Ctr, Royal Victoria Hosp, Div Transplantat Dept Med, Montreal, PQ H3A 1A1, Canada
[2] McGill Univ, Hlth Ctr, Royal Victoria Hosp, Dept Med, Montreal, PQ H3A 1A1, Canada
[3] McGill Univ, Hlth Ctr, Royal Victoria Hosp, Dept Surg, Montreal, PQ H3A 1A1, Canada
[4] McGill Univ, Hlth Ctr, Royal Victoria Hosp, Dept Cardiovasc & Thorac Surg, Montreal, PQ H3A 1A1, Canada
关键词
D O I
10.1097/00007890-200204150-00030
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Solid organ transplant (Tx) patients on calcineurin inhibitors (CNI) can develop acute renal dysfunction (ARD), which could be improved by reducing or withholding ("holiday") CNI dose. Methods. We used anti-CD25 monoclonal antibodies to prevent acute rejection in 11 adult Tx patients (7 heart, 2 liver, 2 heart-renal Tx), requiring a CNI "holiday" because of 15 events of ARD after the initial postTx hospitalization. An event of ARD was defined as an increase in serum creatinine (Scr) > 25% vs. baseline. The CNI "holiday" was implemented until Scr had decreased to baseline. Basiliximab was used in 7 patients (11 events), and daclizumab was used in 4 patients (4 events). Results. The CNI "holiday" was implemented over 21+/-51. days. Anti-CD25 mAb were well tolerated with no episodes of acute rejection. Scr (mumol/liter) increased from 145+/-48 to 301+/-92 (P<0.0001), and decreased to 143+/-55 with the CNI "holiday." Conclusions. Our results suggest that a CNI "holiday" may improve ARD after solid organ Tx without rejection under anti-CD25 mAb coverage.
引用
收藏
页码:1169 / 1172
页数:4
相关论文
共 13 条
[1]  
Billingham M E, 1990, J Heart Transplant, V9, P587
[2]  
CALNE RY, 1978, LANCET, V2, P1323
[3]   A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function [J].
Chang, GJ ;
Mahanty, HD ;
Vincenti, F ;
Freise, CE ;
Roberts, JP ;
Ascher, NL ;
Stock, PG ;
Hirose, R .
CLINICAL TRANSPLANTATION, 2000, 14 (06) :550-554
[4]   CYCLOSPORINE-INDUCED ACUTE RENAL DYSFUNCTION IN THE RAT - EVIDENCE OF ARTERIOLAR VASOCONSTRICTION WITH PRESERVATION OF TUBULAR FUNCTION [J].
ENGLISH, J ;
EVAN, A ;
HOUGHTON, DC ;
BENNETT, WM .
TRANSPLANTATION, 1987, 44 (01) :135-141
[5]  
Hong JC, 2000, TRANSPLANTATION, V69, pS259
[6]   Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation [J].
Kovarik, JM ;
Kahan, BD ;
Rajagopalan, PR ;
Bennett, W ;
Mulloy, LL ;
Gerbeau, C ;
Hall, ML .
TRANSPLANTATION, 1999, 68 (09) :1288-1294
[7]  
MCGIFFIN DC, 1985, HEART TRANSPLANT, V4, P396
[8]   Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients [J].
Nashan, B ;
Moore, R ;
Amlot, P ;
Schmidt, AG ;
Abeywickrama, K ;
Soulillou, JP .
LANCET, 1997, 350 (9086) :1193-1198
[9]  
*NOV PHARM CAN INC, 2000, PROD MON NOV PHARM C
[10]   EFFECTS OF RENAL IMPAIRMENT ON LIVER-TRANSPLANTATION [J].
RIMOLA, A ;
GAVALER, JS ;
SCHADE, RR ;
ELLANKANY, S ;
STARZL, TE ;
VANTHIEL, DH .
GASTROENTEROLOGY, 1987, 93 (01) :148-156